Research programme: adeno-associated viral gene therapies - Coave Therapeutics
Latest Information Update: 28 Aug 2025
At a glance
- Originator Coave Therapeutics
- Developer Coave Therapeutics; Institute of Neurodegenerative Diseases
- Class Antiparkinsonians; Gene therapies; Neuroprotectants
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Multiple system atrophy; Parkinson's disease
- No development reported CNS disorders; Eye disorders
Most Recent Events
- 28 Aug 2025 No recent reports of development identified for preclinical development in CNS-disorders in France
- 28 Aug 2025 No recent reports of development identified for preclinical development in Eye-disorders in France
- 30 Apr 2024 Interim pharmacodynamics data from a preclinical studies in eye disorders released by Coave Therapeutics